Clinical trials: ST Segment Elevation Myocardial Infarction (STEMI)
ST-Segment Elevation Myocardial Infarction
Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction
To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- Trial name
- NCT02075125
- Testing
- Prasugrel 60 mg, Ticagrelor 180 mg
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Dong-A University
Acute Myocardial Infarction
Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction
Available data from randomized trials on thrombectomy in patients with ST-elevation myocardial infarction have shown favourable trends on myocardial reperfusion.
- Trial name
- ATTEMPT (NCT00766740)
- Testing
- thrombectomy devices, angioplasty
- Where
- Italy
- Volunteers
- 2,686 people
- Sponsor
- Catholic University of the Sacred Heart
Multivessel Coronary Artery Disease, STEMI
The Use Of FFR Guided PCI Versus Complete Revascularization and Treatment Of Infarct Related Artery Only In Patients With STEMI
In patients with ST elevation myocardial infarction (STEMI) the treatment goal is revascularization of the occluded artery with the use of primary percutaneous coronary intervention (PCI).
- Conditions
- Multivessel Coronary Artery Disease, STEMI, FFR Guided PCI
- Trial name
- FAIO (NCT02637440)
- Testing
- FFR guided PCI, Angio guided PCI
- Where
- 2 sites in Ireland
- Volunteers
- 560 people
- Sponsor
- University of Limerick
Coronary Artery Disease, Acute Coronary Syndrome
BIOSTEMI Extended Survival
The objective of the BIOSTEMI ES study is to assess the long-term clinical outcomes with the Orsiro ultrathin-strut biodegradable polymer sirolimus-eluting stent compared to the Xience thin-strut durable polymer…
- Trial name
- BIOSTEMI ES (NCT05484310)
- Where
- 10 sites in Switzerland
- Volunteers
- 1,300 people
- Sponsor
- University Hospital, Geneva
STEMI, NSTEMI
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome
The ELECTRA-SIRIO 2 study is a randomized, multicenter, double-blind, investigator-initiated clinical trial aimed to evaluate safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in patients with…
- Conditions
- STEMI, NSTEMI, Unstable Angina
- Trial name
- ELECTRA-SIRIO (NCT04718025)
- Testing
- Ticagrelor 90mg, Ticagrelor 60mg, Aspirin
- Where
- Poland
- Volunteers
- 4,500 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Myocardial Infarction, Coronary Artery Disease
One-Time Complete Revascularization Versus Staged PCI in MVD During Pharmaco-Invasive STEMI Strategy
This study compares two treatment strategies in patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) undergoing a pharmaco-invasive approach after successful fibrinolysis.
- Trial name
- NCT07519590
- Testing
- One-Time Complete Revascularization, Staged Percutaneous Coronary Intervention
- Where
- Egypt
- Volunteers
- 112 people
- Sponsor
- Tanta University
STEMI - ST Elevation Myocardial Infarction
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI patients. The investigators propose to evaluate the clinical efficacy and safety of anticoagulation prolonged for at least 48 hours after…
- Trial name
- RIGHT (NCT03664180)
- Testing
- Bivalirudin, Enoxaparin, Unfractionated heparin
- Where
- China
- Volunteers
- 2,989 people
- Sponsor
- Beijing Anzhen Hospital
STEMI - ST Elevation Myocardial Infarction
Coronary Microcirculation Assessment After Primary Angioplasty in Myocardial Infarction
In the management of acute myocardial infarction treated with primary angioplasty, despite effective epicardial clearance obtained in 95% of cases, microvascular obstruction (MVO) in the damaged territory concerns 50% of…
- Trial name
- NATHANAEL (NCT04542889)
- Testing
- Absolute coronary flow and resistance measurements, IMR measurement
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NSTEMI, NSTE-ACS (NSTEMI and UA)
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI
The objective of this multicentric observational study is to evaluate the prognostic influence of adherence or non-adherence to the recommended coronary angiography timeframe (within 24 hours) and the six-month prognosis of the…
- Conditions
- NSTEMI, NSTE-ACS (NSTEMI and UA), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
- Trial name
- NCT07204847
- Where
- France
- Volunteers
- 407 people
- Sponsor
- University Hospital, Montpellier
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Stable Angina, Unstable Angina
COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate the incidence of bleedings (COSTA-Bleed) and the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with the abluminal…
- Conditions
- Stable Angina, Unstable Angina, STEMI, NSTEMI
- Trial name
- COSTA (NCT02723981)
- Testing
- COMBO-Stent, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran, Any drug eluting stent oder bare metal sent
- Where
- 10 sites in Germany
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
STEMI, Elevated IMR (>32)
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery with a balloon (angioplasty) and a small mesh tube (stent) although life saving…
- Trial name
- RESTORE-MI (NCT03998319)
- Testing
- Tenecteplase (1/3 systemic weight based dose), Sterile water for injection (WFI)
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 445 people
- Sponsor
- University of Sydney
ST Elevation Myocardial Infarction
Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction
To examine the impact of IVUS guidance on clinical outcomes in the patient with Acute ST Segment Elevated Myocardial Infarction.
- Trial name
- LOVEinSTEMI (NCT04063345)
- Testing
- IVUS-guided PCI, Angiography-guided PCI
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Myocardial Infarction
Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary PCI. The hypothesis is, that higher concentration of abciximab i.c.
- Trial name
- NCT00299377
- Testing
- Abciximab i.v., Abciximab i.c.
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- University of Leipzig
Myocardial Infarction
Timing of Complete Revascularization for Multivessel Coronary Artery Disease in STEMI
The study will compare clinical outcomes between complete revascularization during hospitalization for ST elevation myocardial infarction (STEMI) and intervention after 30 days and intervention based on outpatient non-invasive…
- Trial name
- MVD (NCT02756000)
- Testing
- PCI, dobutamine stress echocardiography
- Where
- 4 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Clinical Hospital Center Zemun
ST-segment Elevation Myocardial Infarction, Thrombus
CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial
To compare rheolytic thrombectomy (RT) with manual thrombus aspiration (MTA) in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
- Trial name
- SMART (NCT01281033)
- Testing
- Manual Thrombectomy, AngioJet Rheolytic Thrombectomy (RT) System
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Careggi Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction
This study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with ST-segment elevation myocardial infarction.
- Trial name
- ANGIO-STEMI (NCT06586424)
- Testing
- Anion gap
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Universitas Diponegoro
Acute Myocardial Infarction
Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients
Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater pharmacodynamic inhibition and reduction of cardiovascular events in patients with an acute coronary syndrome.
- Trial name
- ECCLIPSE-STEMI (NCT02929888)
- Testing
- Lysine Acetilsalicilate, Aspirin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.